Specifically, TGF-β1 increases the population of IL-22-producing Th17 cells via activation of PI3K signalling and thereby promotes tumour growth, aggressiveness, and treatment resistance through the subsequent uncontrolled high levels of IL-22 [78]. This evidence concerns the gene TGFB1 and neoplasm.